Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients: Antiviral therapy

D Ferrari, V Spagnuolo, M Manca, A Bigoloni, C Muccini, G Banfi, M Locatelli, A Castagna

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The pilot Phase IIb VIKING study suggested that dolutegravir (DTG), an HIV integrase inhibitor (INI), is efficacious in INI-resistant patients at the 50 mg twice-daily dose. However, DTG response was most reduced in subjects carrying resistance-associated mutations at position G140 and Q148. These mutations can cause a 10-20-fold reduced susceptibility to DTG as well as a 96% lower odds of achieving HIV-1 RNA
Original languageEnglish
Pages (from-to)69-72
Number of pages4
JournalAntiviral Therapy
Volume24
Issue number1
DOIs
Publication statusPublished - 2019

Fingerprint Dive into the research topics of 'Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients: Antiviral therapy'. Together they form a unique fingerprint.

  • Cite this